Amgen 
Welcome,         Profile    Billing    Logout  
 160 Products   813 Diseases   160 Products   1618 Trials   78436 News 


«12...1314151617181920212223...910911»
  • ||||||||||  Nplate (romiplostim) / Amgen, Promacta (eltrombopag) / Novartis
    Journal:  A case with a novel GATA1 variant mimicking immune thrombocytopenia attacks. (Pubmed Central) -  May 5, 2025   
    This situation attracted our attention after the detection of this GATA variant in the etiopathogenesis of thrombocytopenia. Further investigations should be performed for much more rare causes of thrombocytopenia in patients with refractory thrombocytopenia attacks.
  • ||||||||||  Ibrance (palbociclib) / Pfizer
    Journal:  Structural Analysis of Active Pharmaceutical Ingredients in Tablets Using 3D ED/MicroED. (Pubmed Central) -  May 5, 2025   
    In addition, this is the first report of crystal structure elucidation of fexofenadine hydrochloride Form I and palbociclib Form A by single-crystal structure analysis. These results were obtained from randomly selected crystals using the "selected area electron diffraction method", which is one of the outstanding features of 3D ED/MicroED.
  • ||||||||||  Retrospective data, Review, Journal:  Treatment of uveitis in Blau syndrome: A systematic review and meta-analysis. (Pubmed Central) -  May 5, 2025   
    The data show that there is not enough evidence to establish a preferred treatment for managing uveitis in BS. Considering the rarity, the potential severity and refractoriness to current treatments of the disease, there is a critical need for better understanding of pathophysiology and expert driven treatment guidelines for of BS-uveitis.
  • ||||||||||  Lonsurf (trifluridine/tipiracil) / Otsuka, Avastin (bevacizumab) / Roche, Stivarga (regorafenib) / Bayer
    Impact of the KRAS mutation subtype on treatment response in metastatic colorectal cancer (Foyer) -  May 4, 2025 - Abstract #ESMOGI2025ESMO_GI_776;    
    This real-world scenario emphasizes the importance of clinicians being informed while selecting drugs during the sequencing therapy process in refractory mCRC. In pts treated with FTD/TPI with or without bevacizumab, there was no difference in OS and PFS based on the KRAS mutation subtype in this single center cohort.
  • ||||||||||  Stivarga (regorafenib) / Bayer
    Dose escalation STRATegy of regorafenib in Advanced HepatoCellular Carcinoma: Phase II STRATA-HCC trial (Foyer) -  May 4, 2025 - Abstract #ESMOGI2025ESMO_GI_693;    
    P2
    Background: Regorafenib prolonged overall survival (OS) after progression on sorafenib in the phase 3 RESOURCE trial with the standard-dose strategy (160 mg/day orally for 21 days of a 28-day cycle). This single-arm trial demonstrated that a dose-escalation strategy of regorafenib provided treatment benefits with a favorable safety profile, representing an alternative approach after 1st-line therapy.
  • ||||||||||  Lonsurf (trifluridine/tipiracil) / Otsuka, Avastin (bevacizumab) / Roche, Stivarga (regorafenib) / Bayer
    Trifluridine/tipiracil plus bevacizumab (TTB) versus regorafenib (R) in refractory advanced colorectal cancer patients: A real-word evidence efficacy study (Foyer) -  May 4, 2025 - Abstract #ESMOGI2025ESMO_GI_495;    
    A total of 1483 patients met the study criteria, including previous treatment with oxaliplatin, irinotecan and fluoropyrimidine-based chemotherapy (capecitabine or fluorouracil), also with an antiangiogenic drug (bevacizumab, aflibercept or regorafenib) and with an anti-EGFR therapy (cetuximab or panitumumab) as indicated. In this study, based on Real World Data, trifluridine/tipiracil plus bevacizumab was associated with better overall survival compared to regorafenib in refractory advanced colorectal cancer patients.
  • ||||||||||  Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, Vectibix (panitumumab) / Amgen
    Sequence analysis of three different treatment alternatives for patients with left-side RAS wild type metastatic colorectal cancer in Spain (Foyer) -  May 4, 2025 - Abstract #ESMOGI2025ESMO_GI_492;    
    In accordance with clinical practice in Spain, anti-EGFR costs were based on a 50/50 split of cetuximab/panitumumab, anti-VEGF costs on bevacizumab, and CT costs on a 65/35 split of mFOLFOX6/FOLFIRI... The findings suggest that starting with anti-EGFR + CT is the most favorable sequence for the Spanish NHS compared to the rest of analized treatment sequences, providing an additional year of median OS, while being the most efficient targeted therapy in terms of
  • ||||||||||  Stivarga (regorafenib) / Bayer
    The use of regorafenib in cholangiocarcinoma: A real-world data (RWD) review (Foyer) -  May 4, 2025 - Abstract #ESMOGI2025ESMO_GI_466;    
    This cohort of patients often lack effective second line treatment options and in our case, they were older and frailer, making tolerability of further treatment a challenge. Regorafenib has a promising role in cholangiocarcinoma and more studies are needed to evaluate its place in the treatment conundrum.
  • ||||||||||  Fruzaqla (fruquintinib) / Takeda
    Real-world data from fruquintinib in later line metastatic colorectal cancer (Foyer) -  May 4, 2025 - Abstract #ESMOGI2025ESMO_GI_455;    
    Despite the small sample size and very short follow up, we observed a manageable safety profile and an efficacy trend, despite modest outcomes, picturing a highly refractory disease setting and a possible role of previous treatments on VEGFR targeting. We intend to broaden our accrual and increase follow up time to evaluate safety and more mature outcomes.
  • ||||||||||  Neupogen (filgrastim) / Kyowa Kirin, Amgen
    Clinical utility of primary prophylactic filgrastim in resectable esophageal cancer treated with neoadjuvant FLOT therapy (Foyer) -  May 4, 2025 - Abstract #ESMOGI2025ESMO_GI_312;    
    Neoadjuvant 5-FU plus leucovorin, oxaliplatin, docetaxel (FLOT) therapy has demonstrated promising efficacy for ESCC, and is mainly used for patients unfit for cisplatin... The primary prophylactic filgrastim significantly reduced the incidence of grade 3 or higher neutropenia, delay of the 2nd cycle of FLOT therapy, and improved the RDIs of 5-FU and docetaxel in the neoadjuvant FLOT therapy.
  • ||||||||||  everolimus / Generic mfg.
    EZH2 GAIN-OF-FUNCTION MUTATIONS CONFER EVEROLIMUS SENSITIVITY IN DIFFUSE LARGE B CELL LYMPHOMA (Exhibition Area) -  May 4, 2025 - Abstract #ICML2025ICML_858;    
    Our study highlights a link between mTORC1 oncogenic dependence and EZH2 activity in DLBCL, and points to a novel role of EZH2 in mediating cell cycle progression through early G1. EZH2 mutations occur in up to 20% of GCB subtype DLBCL, and our study also suggests a rationale for the use of combined EZH2 and mTOR inhibition in this setting.
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen, Tecvayli (teclistamab-cqyv) / Genmab, J&J
    CHARACTERISTICS OF SECOND PRIMARY MALIGNANCIES FOLLOWING BISPECIFIC ANTIBODIES THERAPY () -  May 4, 2025 - Abstract #ICML2025ICML_582;    
    Myeloid leukemias and non-Hodgkin's lymphoma were more frequent in blinatumomab recipients, while solid malignancies predominated in those treated with teclistamab. Our study provides the first detailed characterization of SPMs post-BsAb, underscoring the need for continued pharmacovigilance and individualized risk management to mitigate SPM risks in patients undergoing BsAbs therapy.
  • ||||||||||  pemrametostat (GSK3326595) / Ipsen, AMG 193 / Amgen
    TARGETING ARGININE METHYLTRANSFERASE PRMT5 AS A PROMISING THERAPEUTIC STRATEGY IN NKTCL () -  May 4, 2025 - Abstract #ICML2025ICML_446;    
    Overall, this study is the first to demonstrate PRMT5 overexpression in NKTCL and its vulnerability to targeted therapy. Both monotherapy with PRMT5 inhibitors and combination treatments show significant antitumor effects, providing new insights for the further treatment of this disease.
  • ||||||||||  Prolia (denosumab) / Amgen
    ADDRESSING HYPERCALCEMIA IN ADULT T-CELL LEUKEMIA/LYMPHOMA () -  May 4, 2025 - Abstract #ICML2025ICML_439;    
    Our analysis demonstrates that while bisphosphonate and calcium lowering agents may contribute to more rapid lowering of calcium, prompt chemotherapy mitigated differences in achieving normal calcium. Future analysis will evaluate initial calcium as predictor of response to therapy, and comparison of agents in managing hypercalcemia.
  • ||||||||||  Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis, Verzenio (abemaciclib) / Eli Lilly
    Review, Journal:  Adjuvant CDK4/6 inhibitors in breast cancer: Interpreting trial design, evidence, and uncertainty. (Pubmed Central) -  May 4, 2025   
    As these agents are incorporated into clinical guidelines, it is critical to clarify whether they improve long-term outcomes, delay recurrence without affecting survival, or cause unintended harm. Impulse to intervene early is understandable, but emerging data must be carefully assessed to ensure adjuvant CDK4/6 inhibition offers meaningful benefit to patients and health systems.
  • ||||||||||  Prolia (denosumab) / Amgen, Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
    Clinical guideline, Journal:  National guidelines for diagnosis and treatment of osteoporosis in Slovakia. (Pubmed Central) -  May 4, 2025   
    Further research is needed to understand the mechanisms and improve risk management strategies. Pharmacologic treatment includes antiresorptive agents (bisphosphonates, denosumab, SERMs), osteoanabolic (teriparatide, romosozumab), and hormone therapy when indicated.
  • ||||||||||  Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis, Verzenio (abemaciclib) / Eli Lilly
    clinical value of bone radiotherapy in a prospective cohort of metastatic breast cancer treated with anti-cdk 4/6 () -  May 3, 2025 - Abstract #ESTRO2025ESTRO_1547;    
    An accurate patient stratification should be prioritized in the near future to develop patient-tailored strategies. Difference among groups were calculated by means of chi- square test for categorical variables or T-Test for continuous variables Our study included forty patients with advanced breast cancer concurrently treated with CDK4/6 inhibitors (palbociclib 30.8%, ribociclib 51.3%, abemaciclib 17.9%) and RT to a total of 131 metastatic lesions included, 30% were over 70 years old (with a mean G8 score of 13.8
  • ||||||||||  Concomitant RT and systemic therapy in breast cancer: Focus on ADCs and CDK4/6i (Strauss 1-2) -  May 3, 2025 - Abstract #ESTRO2025ESTRO_261;    
    Currently, ADC include trastuzumab emtansine (T-DM1), trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan...CDK4/6i include abemaciclib, ribociclib and palbociclib, where the evidence is in favor of using these drugs for first line metastatic therapy of selected patients with hormone positive BC...Few trials have investigated the adverse effects from this combination, whilst most trials have had the combined treatment as an exclusion criterium. When combining drugs with concomitant RT the recommendation is always to be cautious, even in patients where the combination is considered feasible, thus the patient and staff should be aware of the risk of serious adverse effects, e.g. pneumonitis.
  • ||||||||||  Stivarga (regorafenib) / Bayer
    Journal:  Impact of baseline proteinuria on progression-free survival after regorafenib treatment for metastatic colorectal cancer. (Pubmed Central) -  May 3, 2025   
    When combining drugs with concomitant RT the recommendation is always to be cautious, even in patients where the combination is considered feasible, thus the patient and staff should be aware of the risk of serious adverse effects, e.g. pneumonitis. Our results suggest that patients with baseline proteinuria experience poor PFS following regorafenib treatment for mCRC, although we should consider the clinical significance of the difference.
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen
    Journal:  Feedback-responsive cell factories for dynamic modulation of the unfolded protein response. (Pubmed Central) -  May 3, 2025   
    The sense-and-respond systems that mediate dynamic UPR modulation enhance the production of the therapeutic enzyme tissue plasminogen activator and the bispecific antibody blinatumomab. Our feedback-responsive cell factories provide an innovative strategy for dynamically adjusting the innate cellular stress response and enhancing therapeutic protein manufacturing.
  • ||||||||||  Ibrance (palbociclib) / Pfizer
    Journal:  FLT4 activation promotes acute lymphoid leukemia survival through stabilization of MDM2/MDMX and inactivation of p53. (Pubmed Central) -  May 3, 2025   
    Moreover, we found that MDMX Ser-314 phosphorylation, a consensus sequence of CDK4/6, increases MDMX stability, which subsequently affects MDM2 and p53 degradation and could be reversed by the CDK4/6 inhibitor Palbociclib...Consequently, p53 inactivation promotes their survival, proliferation, and resistance to chemotherapy-induced apoptosis. The figure was created in BioRender.com.